Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Ophthalmology

Tracking the Progression of Eye Weakness in arPEO

At a Glance

In arPEO, eye weakness usually progresses slowly: drooping of both eyelids often comes first, followed by reduced eye movement and slower eye shifts used for reading. Tracking these changes helps assess daily safety, while new or sudden double vision needs prompt clinical evaluation.

Living with arPEO means navigating a world that moves faster than your eyes can follow. Because the condition progresses so slowly—often over decades—the changes can be incredibly subtle, making it difficult to pinpoint exactly when they began [1]. Understanding the hallmark symptoms can help you and your care team track these shifts more accurately.

The First Sign: Drooping Eyelids (Ptosis)

For most people, the first noticeable symptom of arPEO is ptosis, or drooping of the upper eyelids [2]. This occurs because the muscles responsible for lifting the lids are among the most energy-intensive in the body and are highly sensitive to mitochondrial dysfunction [3].

  • Bilateral and Gradual: Unlike some other conditions, the drooping in arPEO is usually bilateral (affecting both eyes), though it may be slightly worse on one side than the other [4].
  • Subtle Compensation: You might not realize your lids are drooping at first because you subconsciously compensate. Common signs include constantly raising your eyebrows or tilting your head back (a “chin-up” posture) to see from under the lids [5].
  • A Long Timeline: Ptosis often precedes significant eye-movement issues. In some recorded cases, patients had drooping eyelids for years or even decades before they or their doctors noticed limited eye movement [6][7].

Limited Eye Movement (Ophthalmoplegia)

The second core feature is the gradual loss of the ability to move the eyes, known as ophthalmoplegia [8]. This typically progresses from a slight restriction to a significant loss of motion in all directions.

  • The “Frozen Eye”: In advanced stages, the eyes may become almost completely stationary, or “frozen” [1]. Instead of moving your eyes to look at something, you will likely find yourself rotating your entire head [9].
  • Uneven Restriction: While the loss of movement is generally symmetric, it doesn’t always happen all at once. In some forms of arPEO, such as those related to the POLG gene, looking downward (downgaze) may be preserved until much later in the disease [3].
  • Slowing Down: You might notice that your saccades—the quick, automatic jumps your eyes make when reading or scanning a room—become slower and more difficult [10].

The Mystery of Missing Double Vision

One of the most confusing aspects of arPEO is that even when a patient’s eyes are clearly misaligned (strabismus), they often do not experience diplopia, or double vision [11].

Research in specific cohorts shows that about 60% of patients with these conditions do not report double vision during daily activities [11]. This happens because the brain is remarkably adaptable. Because the eyes lose their range of motion so slowly, the brain has time to undergo sensory suppression—it essentially learns to ignore conflicting visual input from the eyes to prevent confusion [11].

However, this sensory adaptation reduces binocular depth perception, which can affect practical safety. Double vision can still occur, especially if you are tired or if the eye-movement restriction is vertical rather than horizontal [12]. If you do begin seeing new or sudden double vision, it requires prompt clinical assessment, as it is not a normal feature of slow arPEO progression [13].

Early Signs You Might Overlook

Because the symptoms are so gradual, the “start date” of arPEO is often missed. Early clues might include:

  • Fatigue-Related Droop: Eyelids that look slightly heavier at the end of the day or during illness [5]. However, marked day-to-day fluctuation or improvement with rest should prompt your doctor to reassess your diagnosis for Ocular Myasthenia Gravis, as constant, slowly progressive weakness is typical of arPEO.
  • Reading Difficulty: Losing your place on a page because your eyes struggle to make the quick “jump” to the next line [10].
  • Difficulty Tracking: Finding it hard to follow a fast-moving object, such as a ball in a sports game or a car passing by.
  • Stair Safety: Having to look down more deliberately when walking down stairs because your eyes don’t automatically adjust your field of view. Be sure to consider a formal visual-field and driving assessment if your ptosis blocks your field.

While these symptoms are life-altering, they are typically limited to the muscles around the eyes in “isolated” arPEO. If you notice symptoms beyond the eyes, such as significant limb weakness or balance issues, it is important to discuss these with your doctor, as they may point toward a “PEO-plus” presentation, which is covered in our section on multisystem monitoring [14].

Common questions in this guide

What is usually the first sign of arPEO?
Gradual drooping of the upper eyelids, called ptosis, is often the first noticeable sign of arPEO. It usually affects both eyes and may appear years or even decades before eye movement becomes clearly limited.
How does eye movement loss change over time in arPEO?
Eye movement usually becomes restricted gradually, often in several directions. The quick eye movements used for reading and scanning may slow, and in advanced disease the eyes can become nearly stationary, leading a person to turn the whole head instead.
Why might I not see double even if my eyes are misaligned?
When eye movement changes slowly, the brain may learn to ignore the conflicting image from one eye. This can prevent noticeable double vision but may reduce depth perception; double vision can still appear when you are tired or when vertical eye movement is more affected.
Are fluctuating eyelids typical of arPEO?
ArPEO usually causes weakness that is constant and slowly progressive rather than marked day-to-day fluctuation. Drooping that clearly improves with rest or varies substantially should be discussed with a doctor because another condition, such as ocular myasthenia, may need to be considered.
What daily activities can arPEO eye weakness affect?
Slower eye movements or drooping eyelids can make reading, following moving objects, scanning shelves, and walking down stairs more difficult. If ptosis blocks part of your visual field, ask about a formal visual-field and driving assessment.
What should be measured when monitoring arPEO eye weakness?
Your clinician may record eyelid position, eyelid-lifting muscle function, the range of gaze in each direction, and the speed of quick eye movements. These measurements provide a baseline and help show whether changes are affecting reading, mobility, or driving safety.
When might treatment for drooping eyelids be considered?
Ptosis surgery or a device called a ptosis crutch may be discussed when drooping interferes with vision or daily activities. The right option depends on eyelid function, the amount of visual-field blockage, and your overall eye movement.

Get notified when new evidence is published on Autosomal recessive progressive external ophthalmoplegia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (14)
  1. 1

    Clinicogenetical Variants of Progressive External Ophthalmoplegia - An Especial Review of Non-ophthalmic Manifestations.

    Maghbooli M, Ghaffarpour M, Ghazizadeh T, et al.

    Neurology India 2020; (68(4)):760-768 doi:10.4103/0028-3886.293454.

    PMID: 32859811
  2. 2

    Progressive External Ophthalmoplegia.

    McClelland C, Manousakis G, Lee MS

    Current neurology and neuroscience reports 2016; (16(6)):53 doi:10.1007/s11910-016-0652-7.

    PMID: 27072953
  3. 3

    Changing faces of mitochondrial disease: autosomal recessive POLG disease mimicking myasthenia gravis and progressive supranuclear palsy.

    Elwan M, Schaefer AM, Craig K, et al.

    BMJ neurology open 2022; (4(2)):e000352 doi:10.1136/bmjno-2022-000352.

    PMID: 36518302
  4. 4

    Late-Onset Development of Eyelid Ptosis in Chronic Progressive External Ophthalmoplegia: A 30-Year Follow-up.

    Murdock J, Thyparampil PJ, Yen MT

    Neuro-ophthalmology (Aeolus Press) 2016; (40(1)):44-46 doi:10.3109/01658107.2015.1122815.

    PMID: 27928383
  5. 5

    Type and Frequency of Misdiagnosis and Time Lag to Diagnosis in Patients with Chronic Progressive External Ophthalmoplegia.

    Karimi N, Ghahvehchian H, Keyhani A, et al.

    Journal of ophthalmic & vision research 2024; (19(3)):334-339 doi:10.18502/jovr.v19i3.13998.

    PMID: 39359531
  6. 6

    Atheromatosis of the Scalp: A Novel Feature of Chronic Progressive External Ophthalmoplegia Plus Due to a Single Mitochondrial DNA Deletion.

    Finsterer J

    Cureus 2021; (13(12)):e20641 doi:10.7759/cureus.20641.

    PMID: 35103203
  7. 7

    Disclosing the functional changes of two genetic alterations in a patient with Chronic Progressive External Ophthalmoplegia: Report of the novel mtDNA m.7486G>A variant.

    Bacalhau M, Simões M, Rocha MC, et al.

    Neuromuscular disorders : NMD 2018; (28(4)):350-360 doi:10.1016/j.nmd.2017.11.006.

    PMID: 29398297
  8. 8

    Simplifying the clinical classification of polymerase gamma (POLG) disease based on age of onset; studies using a cohort of 155 cases.

    Hikmat O, Naess K, Engvall M, et al.

    Journal of inherited metabolic disease 2020; (43(4)):726-736 doi:10.1002/jimd.12211.

    PMID: 32391929
  9. 9

    Clinical, neuroelectrophysiological and muscular pathological analysis of chronic progressive external ophthalmoplegia.

    Lv H, Qu Q, Liu H, et al.

    Experimental and therapeutic medicine 2020; (20(2)):1770-1774 doi:10.3892/etm.2020.8822.

    PMID: 32742407
  10. 10

    Chronic Progressive External Ophthalmoplegia in the Absence of Ptosis.

    Bucelli RC, Lee MS, McClelland CM

    Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 2016; (36(3)):270-4 doi:10.1097/WNO.0000000000000384.

    PMID: 27111092
  11. 11

    Ophthalmological signs and sensorimotor evaluation in mitochondrial chronic progressive external ophthalmoplegia: a multidisciplinary prospective study.

    Savino G, Giannuzzi F, Cima V, et al.

    BMC ophthalmology 2025; (25(1)):520 doi:10.1186/s12886-025-04194-6.

    PMID: 41029504
  12. 12

    Strabismus in chronic progressive external ophthalmoplegia.

    Kim JY, Yang HK, Kim N, et al.

    Acta ophthalmologica 2021; (99(2)):e274-e280 doi:10.1111/aos.14558.

    PMID: 33191655
  13. 13

    Strabismus surgery for diplopia in chronic progressive external ophthalmoplegia.

    Chatzistefanou KI, Brouzas D, Asproudis I, et al.

    International ophthalmology 2019; (39(1)):213-217 doi:10.1007/s10792-017-0781-2.

    PMID: 29582258
  14. 14

    RNASEH1 Mutations Impair mtDNA Replication and Cause Adult-Onset Mitochondrial Encephalomyopathy.

    Reyes A, Melchionda L, Nasca A, et al.

    American journal of human genetics 2015; (97(1)):186-93.

    PMID: 26094573

This page is for informational purposes only and does not constitute medical advice. An eye specialist should assess new double vision or other changes in vision and discuss monitoring or treatment options.